Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository.

Efthymiou M, Mackie IJ, Lane PJ, Andrade D, Willis R, Erkan D, Sciascia S, Krillis S, Bison E, Borges Galhardo Vendramini M, Romay-Penabad Z, Qi M, Tektonidou M, Ugarte A, Chighizola C, Belmont HM, Aguirre MA, Ji L, Branch DW, de Jesus G, Fortin PR, Andreoli L, Petri M, Cervera R, Rodriguez E, Knight JS, Atsumi T, Vega J, Sevim E, Bertolaccini ML, Pengo V, Cohen H; APS ACTION.

J Thromb Haemost. 2019 Jul 30. doi: 10.1111/jth.14596. [Epub ahead of print]

PMID:
31364274
2.

Treatment in thrombotic antiphospholipid syndrome: a review.

Vadgama TS, Smith A, Bertolaccini ML.

Lupus. 2019 Sep;28(10):1181-1188. doi: 10.1177/0961203319864163. Epub 2019 Jul 26.

PMID:
31345117
3.

The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort.

Radin M, Sciascia S, Erkan D, Pengo V, Tektonidou MG, Ugarte A, Meroni P, Ji L, Belmont HM, Cohen H, Ramires de Jesús G, Branch DW, Fortin PR, Andreoli L, Petri M, Rodriguez E, Rodriguez-Pinto I, Knight JS, Atsumi T, Willis R, Gonzalez E, Lopez-Pedrera R, Rossi Gandara AP, Borges Gualhardo Vendramini M, Banzato A, Sevim E, Barbhaiya M, Efthymiou M, Mackie I, Bertolaccini ML, Andrade D; APS ACTION.

Semin Arthritis Rheum. 2019 May 2. pii: S0049-0172(19)30090-3. doi: 10.1016/j.semarthrit.2019.04.009. [Epub ahead of print]

PMID:
31153708
4.

The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis.

Sciascia S, Willis R, Pengo V, Krilis S, Andrade D, Tektonidou MG, Ugarte A, Chighizola C, Branch DW, Levy RA, Nalli C, Fortin PR, Petri M, Rodriguez E, Rodriguez-Pinto I, Atsumi T, Nascimento I, Rosa R, Banzato A, Erkan D, Cohen H, Efthymiou M, Mackie I, Bertolaccini ML; APS ACTION.

Thromb Res. 2019 Mar;175:32-36. doi: 10.1016/j.thromres.2019.01.010. Epub 2019 Jan 18.

PMID:
30685523
5.

Application of different lupus anticoagulant diagnostic algorithms to the same assay data leads to interpretive discrepancies in some samples.

Moore GW, Maloney JC, de Jager N, Dunsmore CL, Gorman DK, Polgrean RF, Bertolaccini ML.

Res Pract Thromb Haemost. 2017 Jun 20;1(1):62-68. doi: 10.1002/rth2.12006. eCollection 2017 Jul.

6.

Recent advances in the management of systemic lupus erythematosus.

Sciascia S, Radin M, Roccatello D, Sanna G, Bertolaccini ML.

F1000Res. 2018 Jun 29;7. pii: F1000 Faculty Rev-970. doi: 10.12688/f1000research.13941.1. eCollection 2018. Review.

7.

Clinical utility of the global anti-phospholipid syndrome score for risk stratification: a pooled analysis.

Sciascia S, Radin M, Sanna G, Cecchi I, Roccatello D, Bertolaccini ML.

Rheumatology (Oxford). 2018 Apr 1;57(4):661-665. doi: 10.1093/rheumatology/kex466. Review.

8.

Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconvertion?

Sciascia S, Coloma-Bazán E, Radin M, Bertolaccini ML, López-Pedrera C, Espinosa G, Meroni PL, Cervera R, Cuadrado MJ.

Autoimmun Rev. 2017 Nov;16(11):1109-1114. doi: 10.1016/j.autrev.2017.09.004. Epub 2017 Sep 9. Review.

PMID:
28899804
9.

Closing the Serological Gap in the Antiphospholipid Syndrome: The Value of "Non-criteria" Antiphospholipid Antibodies.

Zohoury N, Bertolaccini ML, Rodriguez-Garcia JL, Shums Z, Ateka-Barrutia O, Sorice M, Norman GL, Khamashta M.

J Rheumatol. 2017 Nov;44(11):1597-1602. doi: 10.3899/jrheum.170044. Epub 2017 Sep 1.

10.

The Clinical Relevance of Noncriteria Antiphospholipid Antibodies.

Bertolaccini ML, Sanna G.

Semin Thromb Hemost. 2018 Jul;44(5):453-457. doi: 10.1055/s-0037-1601328. Epub 2017 May 3. Review.

PMID:
28470650
11.

Recent advances in understanding antiphospholipid syndrome.

Bertolaccini ML, Sanna G.

F1000Res. 2016 Dec 22;5:2908. doi: 10.12688/f1000research.9717.1. eCollection 2016. Review.

12.

Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial.

Cohen H, Hunt BJ, Efthymiou M, Arachchillage DR, Mackie IJ, Clawson S, Sylvestre Y, Machin SJ, Bertolaccini ML, Ruiz-Castellano M, Muirhead N, Doré CJ, Khamashta M, Isenberg DA; RAPS trial investigators.

Lancet Haematol. 2016 Sep;3(9):e426-36. doi: 10.1016/S2352-3026(16)30079-5.

13.

Evaluation of phosphatidylserine-dependent antiprothrombin antibody testing for the diagnosis of antiphospholipid syndrome: results of an international multicentre study.

Amengual O, Forastiero R, Sugiura-Ogasawara M, Otomo K, Oku K, Favas C, Delgado Alves J, Žigon P, Ambrožič A, Tomšič M, Ruiz-Arruza I, Ruiz-Irastorza G, Bertolaccini ML, Norman GL, Shums Z, Arai J, Murashima A, Tebo AE, Gerosa M, Meroni PL, Rodriguez-Pintó I, Cervera R, Swadzba J, Musial J, Atsumi T.

Lupus. 2017 Mar;26(3):266-276. doi: 10.1177/0961203316660203. Epub 2016 Aug 20.

PMID:
27510605
14.

Autoantibodies to domain 1 of beta 2 glycoprotein I determined using a novel chemiluminescence immunoassay demonstrate association with thrombosis in patients with antiphospholipid syndrome.

Mahler M, Albesa R, Zohoury N, Bertolaccini ML, Ateka-Barrutia O, Rodriguez-Garcia JL, Norman GL, Khamashta M.

Lupus. 2016 Jul;25(8):911-6. doi: 10.1177/0961203316640366.

PMID:
27252269
15.

Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome.

Bertolaccini ML, Contento G, Lennen R, Sanna G, Blower PJ, Ma MT, Sunassee K, Girardi G.

J Autoimmun. 2016 Dec;75:30-38. doi: 10.1016/j.jaut.2016.04.008. Epub 2016 May 6.

16.

Antibodies to domain I of β-2-glycoprotein I and IgA antiphospholipid antibodies in patients with 'seronegative' antiphospholipid syndrome.

Cousins L, Pericleous C, Khamashta M, Bertolaccini ML, Ioannou Y, Giles I, Rahman A.

Ann Rheum Dis. 2015 Jan;74(1):317-9. doi: 10.1136/annrheumdis-2014-206483. Epub 2014 Oct 30. No abstract available.

17.

Antibodies to phosphatidylserine/prothrombin complex and the antiphospholipid syndrome.

Sciascia S, Bertolaccini ML.

Lupus. 2014 Oct;23(12):1309-12. doi: 10.1177/0961203314538332.

18.

Thrombotic risk assessment in APS: the Global APS Score (GAPSS).

Sciascia S, Bertolaccini ML.

Lupus. 2014 Oct;23(12):1286-7. doi: 10.1177/0961203314541317.

19.

The global anti-phospholipid syndrome score in primary APS.

Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML.

Rheumatology (Oxford). 2015 Jan;54(1):134-8. doi: 10.1093/rheumatology/keu307. Epub 2014 Aug 13.

20.

Thrombotic risk assessment in systemic lupus erythematosus: validation of the global antiphospholipid syndrome score in a prospective cohort.

Sciascia S, Cuadrado MJ, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML.

Arthritis Care Res (Hoboken). 2014 Dec;66(12):1915-20. doi: 10.1002/acr.22388.

21.

Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus: a systematic review.

Sciascia S, Bertolaccini ML, Roccatello D, Khamashta MA, Sanna G.

J Neurol. 2014 Sep;261(9):1706-14. doi: 10.1007/s00415-014-7406-8. Epub 2014 Jun 21. Review.

22.

The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review.

Sciascia S, Sanna G, Khamashta MA, Cuadrado MJ, Erkan D, Andreoli L, Bertolaccini ML; APS Action.

Ann Rheum Dis. 2015 Nov;74(11):2028-33. doi: 10.1136/annrheumdis-2014-205663. Epub 2014 Jun 18. Review.

23.

14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends.

Bertolaccini ML, Amengual O, Andreoli L, Atsumi T, Chighizola CB, Forastiero R, de Groot P, Lakos G, Lambert M, Meroni P, Ortel TL, Petri M, Rahman A, Roubey R, Sciascia S, Snyder M, Tebo AE, Tincani A, Willis R.

Autoimmun Rev. 2014 Sep;13(9):917-30. doi: 10.1016/j.autrev.2014.05.001. Epub 2014 May 10. Review.

PMID:
24824074
24.

Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment.

Ruiz-Limon P, Barbarroja N, Perez-Sanchez C, Aguirre MA, Bertolaccini ML, Khamashta MA, Rodriguez-Ariza A, Almadén Y, Segui P, Khraiwesh H, Gonzalez-Reyes JA, Villalba JM, Collantes-Estevez E, Cuadrado MJ, Lopez-Pedrera C.

Ann Rheum Dis. 2015 Jul;74(7):1450-8. doi: 10.1136/annrheumdis-2013-204351. Epub 2014 Mar 21.

PMID:
24658835
25.

New tests to detect antiphospholipid antibodies: antiprothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies.

Sciascia S, Khamashta MA, Bertolaccini ML.

Curr Rheumatol Rep. 2014 May;16(5):415. doi: 10.1007/s11926-014-0415-x.

26.

Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients.

Cervera R, Serrano R, Pons-Estel GJ, Ceberio-Hualde L, Shoenfeld Y, de Ramón E, Buonaiuto V, Jacobsen S, Zeher MM, Tarr T, Tincani A, Taglietti M, Theodossiades G, Nomikou E, Galeazzi M, Bellisai F, Meroni PL, Derksen RH, de Groot PG, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris JC, Quéré I, Hachulla E, Vasconcelos C, Fernández-Nebro A, Haro M, Amoura Z, Miyara M, Tektonidou M, Espinosa G, Bertolaccini ML, Khamashta MA; Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies).

Ann Rheum Dis. 2015 Jun;74(6):1011-8. doi: 10.1136/annrheumdis-2013-204838. Epub 2014 Jan 24.

27.

Validation of a commercially available kit to detect anti-phosphatidylserine/prothrombin antibodies in a cohort of systemic lupus erythematosus patients.

Sciascia S, Sanna G, Murru V, Khamashta MA, Bertolaccini ML.

Thromb Res. 2014 Mar;133(3):451-4. doi: 10.1016/j.thromres.2013.12.001. Epub 2013 Dec 7.

28.

Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review.

Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML.

Thromb Haemost. 2014 Feb;111(2):354-64. doi: 10.1160/TH13-06-0509. Epub 2013 Oct 31. Review.

29.

Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS).

Cuadrado MJ, Bertolaccini ML, Seed PT, Tektonidou MG, Aguirre A, Mico L, Gordon C, Ruiz-Irastorza G, Egurbide MV, Gil A, Espinosa G, Houssiau F, Rahman A, Martin H, McHugh N, Galindo M, Akil M, Amigo MC, Murru V, Khamashta MA.

Rheumatology (Oxford). 2014 Feb;53(2):275-84. doi: 10.1093/rheumatology/ket313. Epub 2013 Oct 4.

PMID:
24097288
30.

Antiphosphatidylserine/prothrombin antibodies in systemic lupus erythematosus.

Bertolaccini ML, Sciascia S, Sanna G, Khamashta MA.

J Rheumatol. 2013 Sep;40(9):1620. doi: 10.3899/jrheum.130295. No abstract available.

PMID:
23996998
31.

Long-term follow-up of young adults with stroke.

Sciascia S, Bertolaccini ML, Ateka-Barrutia O.

JAMA. 2013 Jul 17;310(3):321. doi: 10.1001/jama.2013.7924. No abstract available.

PMID:
23860993
32.

GAPSS: the Global Anti-Phospholipid Syndrome Score.

Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML.

Rheumatology (Oxford). 2013 Aug;52(8):1397-403. doi: 10.1093/rheumatology/kes388. Epub 2013 Jan 12.

33.

Prevalence of antibodies to prothrombin in solid phase (aPT) and to phosphatidylserine-prothrombin complex (aPS/PT) in patients with and without lupus anticoagulant.

Bertolaccini ML, Sciascia S, Murru V, Garcia-Fernandez C, Sanna G, Khamashta MA.

Thromb Haemost. 2013 Feb;109(2):207-13. doi: 10.1160/TH12-07-0527. Epub 2012 Dec 20.

PMID:
23254928
34.

The clinical value of testing for antibodies to phosphatidylethanolamine (aPE) in patients with systemic lupus erythematosus (SLE).

Bertolaccini ML, Murru V, Sciascia S, Sanna G, Khamashta MA.

Thromb Res. 2012 Dec;130(6):914-8. doi: 10.1016/j.thromres.2012.06.008. Epub 2012 Oct 15.

PMID:
23079292
35.

Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities.

Sciascia S, Murru V, Sanna G, Roccatello D, Khamashta MA, Bertolaccini ML.

J Thromb Haemost. 2012 Dec;10(12):2512-8. doi: 10.1111/jth.12014.

36.

The clinical relevance of IgA anticardiolipin and IgA anti-β2 glycoprotein I antiphospholipid antibodies: a systematic review.

Meijide H, Sciascia S, Sanna G, Khamashta MA, Bertolaccini ML.

Autoimmun Rev. 2013 Jan;12(3):421-5. doi: 10.1016/j.autrev.2012.08.002. Epub 2012 Aug 19. Review.

37.

Central nervous system involvement in systemic lupus erythematosus: Overview on classification criteria.

Sciascia S, Bertolaccini ML, Baldovino S, Roccatello D, Khamashta MA, Sanna G.

Autoimmun Rev. 2013 Jan;12(3):426-9. doi: 10.1016/j.autrev.2012.08.014. Epub 2012 Aug 25. Review.

38.

Independent validation of the antiphospholipid score for the diagnosis of antiphospholipid syndrome.

Sciascia S, Bertolaccini ML, Roccatello D, Khamashta MA.

Ann Rheum Dis. 2013 Jan;72(1):142-3. doi: 10.1136/annrheumdis-2012-201985. Epub 2012 Jul 28. No abstract available.

39.

Anti-phosphatidylethanolamine antibody, thromboembolic events and the antiphospholipid syndrome.

Staub HL, Bertolaccini ML, Khamashta MA.

Autoimmun Rev. 2012 Dec;12(2):230-4. doi: 10.1016/j.autrev.2012.07.008. Epub 2012 Jul 13. Review.

PMID:
22796282
40.

Antibodies to prothrombin.

Bertolaccini ML.

Lupus. 2012 Jun;21(7):729-31. doi: 10.1177/0961203312443299. Review.

PMID:
22635215
41.

Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q(10) treatment.

Perez-Sanchez C, Ruiz-Limon P, Aguirre MA, Bertolaccini ML, Khamashta MA, Rodriguez-Ariza A, Segui P, Collantes-Estevez E, Barbarroja N, Khraiwesh H, Gonzalez-Reyes JA, Villalba JM, Velasco F, Cuadrado MJ, Lopez-Pedrera C.

Blood. 2012 Jun 14;119(24):5859-70. doi: 10.1182/blood-2011-12-400986. Epub 2012 Apr 23.

PMID:
22529290
42.

Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called 'seronegative APS').

Rodriguez-Garcia JL, Bertolaccini ML, Cuadrado MJ, Sanna G, Ateka-Barrutia O, Khamashta MA.

Ann Rheum Dis. 2012 Feb;71(2):242-4. doi: 10.1136/annrheumdis-2011-200614. Epub 2011 Sep 27.

PMID:
21953349
43.

[Autoantibodies and systemic vasculitis].

Alba P, Bertolaccini ML, Khasmashta M.

Rev Fac Cien Med Univ Nac Cordoba. 2010;67(4):159-68. Review. Spanish. No abstract available.

PMID:
21843440
44.

'Non-criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010.

Bertolaccini ML, Amengual O, Atsumi T, Binder WL, de Laat B, Forastiero R, Kutteh WH, Lambert M, Matsubayashi H, Murthy V, Petri M, Rand JH, Sanmarco M, Tebo AE, Pierangeli SS.

Lupus. 2011 Feb;20(2):191-205. doi: 10.1177/0961203310397082.

PMID:
21303836
45.

Diagnosis of antiphospholipid syndrome.

Bertolaccini ML, Khamashta MA.

Expert Rev Hematol. 2008 Dec;1(2):183-8. doi: 10.1586/17474086.1.2.183. Review.

PMID:
21082923
46.

Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients.

Cervera R, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Kiss E, Zeher MM, Tincani A, Kontopoulou-Griva I, Galeazzi M, Bellisai F, Meroni PL, Derksen RH, de Groot PG, Gromnica-Ihle E, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris JC, Quéré I, Hachulla E, Vasconcelos C, Roch B, Fernández-Nebro A, Piette JC, Espinosa G, Bucciarelli S, Pisoni CN, Bertolaccini ML, Boffa MC, Hughes GR; Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies).

Ann Rheum Dis. 2009 Sep;68(9):1428-32. doi: 10.1136/ard.2008.093179. Epub 2008 Sep 18.

PMID:
18801761
47.

Migraine and antiphospholipid antibodies: no association found in migraine-discordant monozygotic twins.

Williams FM, Cherkas LF, Bertolaccini ML, Murru V, Surdulescu GL, Hughes GR, Khamashta MA, Spector TD, MacGregor AJ.

Cephalalgia. 2008 Oct;28(10):1048-52. doi: 10.1111/j.1468-2982.2008.01646.x. Epub 2008 Jul 9.

PMID:
18624800
48.

Neuropsychiatric involvement in systemic lupus erythematosus: current therapeutic approach.

Sanna G, Bertolaccini ML, Khamashta MA.

Curr Pharm Des. 2008;14(13):1261-9. Review.

PMID:
18537650
49.

The use of laboratory methods in differential diagnosis and treatment of SLE and antiphospholipid syndrome.

Alba P, Bertolaccini ML, Khamashta MA.

Expert Rev Clin Immunol. 2007 Jul;3(4):613-22. doi: 10.1586/1744666X.3.4.613.

PMID:
20477165
50.

Lack of association of antibodies to ribosomal P proteins with lupus membranous glomerulonephritis: comment on the article by Do Nascimento et al.

Bertolaccini ML, Murru V, Alba P, Khamashta MA.

Arthritis Rheum. 2006 Dec;54(12):4025-6; author reply 4026-7. No abstract available.

Supplemental Content

Loading ...
Support Center